cAd3-ZEBOV

from Wikipedia, the free encyclopedia

cAd3-ZEBOV is an experimental recombinant vaccine against Ebola virus .

properties

cAd3-ZEBOV is a viral vector based on chimpanzee adenovirus type 3 (chAdV3). To generate the vaccine, a gene from the Ebola virus was inserted into its genome , which encodes the viral glycoproteins (GP) of the Zaire Ebola virus and the Sudan Ebola virus . It is administered by intramuscular injection. cAd3-ZEBOV was developed by GlaxoSmithKline . The vaccine began clinical trials in September 2014 .

Individual evidence

  1. First British volunteer injected with Ebola vaccine trial in Oxford . In: The Guardian , September 17, 2014.
  2. An Ebola vaccine was given to 10 volunteers, and there are 'no red flags' yet . In: Washington Post , September 16, 2014.